A multicentre randomised phase II clinical trial comparing oxaliplatin (Eloxatin), capecitabine (Xeloda) and pre-operative radiotherapy with or without cetuximab followed by total mesorectal excision for the treatment of patients with magnetic resonance imaging (MRI) defined high risk rectal cancer.

Trial Profile

A multicentre randomised phase II clinical trial comparing oxaliplatin (Eloxatin), capecitabine (Xeloda) and pre-operative radiotherapy with or without cetuximab followed by total mesorectal excision for the treatment of patients with magnetic resonance imaging (MRI) defined high risk rectal cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Cetuximab (Primary) ; Capecitabine; Oxaliplatin
  • Indications Rectal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms EXPERT-C; EXPERT-RCT
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 11 Oct 2016 Results analysing KRAS mutations in circulating tumour DNA in patients with MRI-defined, high-risk, locally-advanced rectal cancer patients from the EXPERT-C trial, presented at the 41st European Society for Medical Oncology Congress
    • 23 May 2016 Results of a pooled analysis from EXPERT and EXPERT-C trials (n=269) published in the Annals of Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top